Werewolf Therapeutics initiated with an Outperform at JMP Securities

JMP Securities initiated coverage of Werewolf Therapeutics with an Outperform rating and $12 price target. The analyst believes Werewolf’s Predator platform may lead a potential renaissance in the immunotherapy field. Focusing on scientifically established targets, preclinical results have shown a clear differentiation of WTX-124 compared to the administration of IL-2, the analyst tells investors in a research note. The firm says Werewolf represents an interesting investment opportunity, whose shares are attractively priced.